Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

K. V. Albuquerque, M. R. Price, R. A. Badley, I. Jonrup, D. Pearson, R. W. Blamey, J. F R Robertson

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

The value of pre-treatment serum tumour marker levels in 85 consecutive patients of newly diagnosed metastatic breast cancer was prospectively assessed for predicting response to therapy and survival. The markers studied were carcinoembryonic antigen (CEA), orosomucoid (ORO), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), ferritin (FERR), human milk fat globule membrane 1 and 2 (HMFGI and 2), CA 15-3 and NCRC-11. There was no correlation between serum marker levels and response to therapy. Only serum concentrations of CRP (P = 0.02), FERR (P = 0.001), HMFG1 (P = 0.004) and HMFG2 (P = 0.04) were predictive for survival. The prognostic significance of HMFG1 was restricted to a minority of patients (7%) with extreme values of these serum markers.

Original languageEnglish (US)
Pages (from-to)504-509
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume21
Issue number5
DOIs
StatePublished - Oct 1995

Keywords

  • metastatic breast cancer
  • overall survival
  • tumour markers

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival'. Together they form a unique fingerprint.

Cite this